Opinion

Video

The current treatment landscape of mHSPC

Explore the latest advancements in metastatic hormone-sensitive prostate cancer treatment, highlighting effective agents and clinical trial outcomes.

Treatment Options for mHSPC

Key Themes:

  • Current 2025 guidelines recommend ADT with intensification.
  • Multiple intensification options include abiraterone, darolutamide, and docetaxel.
  • Key clinical trials include ARANOTE, ARASENS, and TITAN.
  • All studies demonstrate survival benefit and delayed disease progression with intensification.

Key Points for Physicians:

  • ADT monotherapy is no longer the standard of care.
  • Multiple evidence-based intensification options exist.
  • Selection can be tailored based on patient characteristics and preferences.
  • All intensification approaches demonstrate benefit over ADT alone.

Notable Insights: The evolution to combination therapy approaches represents a significant paradigm shift in the management of mHSPC, with multiple effective options now available.

Clinical Significance: The established benefit of intensification therapy has fundamentally changed the treatment landscape for mHSPC, providing multiple evidence-based approaches to improve outcomes.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
3 experts are featured in this series.
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.